NCT03333369View on ClinicalTrials.gov

Exceptional Experiences (EE), Salience & Dopaminergic Neurotransmission

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

May 15, 2014

Primary Completion Date

August 13, 2015

Study Completion Date

August 13, 2015

Conditions
HealthySchizotypal Personality
Interventions
DRUG

200 mg levodopa/50 mg benserazide

DRUG

Dextrose

Trial Locations (1)

8006 Zürich

Collegium Helveticum, ETH & Universität Zürich, Zurich

All Listed Sponsors
collaborator

Swiss Federal Institute of Technology

OTHER

lead

University of Zurich

OTHER

NCT03333369 - Exceptional Experiences (EE), Salience & Dopaminergic Neurotransmission | Biotech Hunter | Biotech Hunter